FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS

生物活性化合物的功能化同系物

基本信息

项目摘要

Recent work in our laboratory has demonstrated that certain drugs may be attached to well-defined "carrier" molecules and still retain the ability to bind to the receptor site and effect biological activity. This synthetic strategy for the attachment of drugs to carriers is termed the "functionalized cogener" approach. The "carrier" molecule may be many times larger than the parent drug; indeed there is practically no maximum site limitation for a fully potent analog. Unlike the prodrug approach or the immobilization of drugs for slow releases, the "functionalized cogener" approach is designed to produce analogs for which no metabolic cleavage step is necessary for activation. Moreover, the attachment of the drug to a "carrier" such as a peptide may result in enhanced affinity at an extracellular receptor site and an improvement in the pharmacological profile of the parent drug. Purine derivatives containing attached chains were developed as functionalized cogeners for adenosine receptors. Reporter groups such as fluorescent dyes have been covalently attached resulting in receptor probes of relatively high affinity. Sites for chain derivatization on the structures of telenzepine and pirenzepine (useful drugs in treating stomach ulcers and as research tools for the brain), two selective muscarinic antagonists, have been located. In a series of amino alkyl derivatives, it was found that increasing the chain length enhances the potency of the derivatives as a muscarinic antagonist. By incorporation of a phenyl isothiocyanate group, chemically reactive affinity labels for muscarinic receptors were developed. Other reporter groups included in the telenzepine series include biotin, p-aminophenylacetyl (for preparing radiotracers and photoaffinity labeling reagents), and fluorescent dyes fluorescein and tetramethylrhodamines (for locating the receptor sites microscopically and for binding assays that do not require the use of radioisotopes).
我们实验室最近的研究表明,某些药物可能

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

K JACOBSON其他文献

K JACOBSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('K JACOBSON', 18)}}的其他基金

FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3875623
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3776296
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    3839858
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    3754192
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3964198
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    5201968
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    4689207
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDES
用于功能化药物和肽的放射性标记的辅基
  • 批准号:
    3776297
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    3776298
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3754190
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Development of Affinity Labeling Approaches for Protein Identification
蛋白质鉴定亲和标记方法的开发
  • 批准号:
    554025-2020
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
Design of a novel affinity labeling probe exhibiting fluorescence and luminescence
一种新型亲和标记探针的设计,具有荧光和发光功能
  • 批准号:
    16K17930
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Affinity Labeling the Dopamine Transporter Active Site
多巴胺转运蛋白活性位点的亲和标记
  • 批准号:
    6731145
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
Affinity Labeling the Dopamine Transporter Active Site
多巴胺转运蛋白活性位点的亲和标记
  • 批准号:
    6868946
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
Affinity Labeling the Dopamine Transporter Active Site
多巴胺转运蛋白活性位点的亲和标记
  • 批准号:
    6579786
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
SGER: X-ray Crystallographic and Affinity Labeling Analysis of the Structure of Rat Epididymal N-Acetyl-B-D-hexosaminidase: Insight into the Catalytic Mechanism
SGER:大鼠附睾 N-乙酰基-B-D-氨基己糖苷酶结构的 X 射线晶体学和亲和标记分析:深入了解催化机制
  • 批准号:
    9804595
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Affinity Labeling of Nucleotide Sites in Proteins
蛋白质中核苷酸位点的亲和标记
  • 批准号:
    9728202
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
谷胱甘肽 S 转移酶的亲和标记
  • 批准号:
    2654163
  • 财政年份:
    1996
  • 资助金额:
    --
  • 项目类别:
AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
谷胱甘肽 S 转移酶的亲和标记
  • 批准号:
    2871848
  • 财政年份:
    1996
  • 资助金额:
    --
  • 项目类别:
AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
谷胱甘肽 S 转移酶的亲和标记
  • 批准号:
    2330915
  • 财政年份:
    1996
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了